MILTON, ONTARIO--(Marketwired - Jan 4, 2016) - Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(TBUFF) ("Tribute" or the "Company"), a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,632,375, entitled "Diclofenac Formulations and Method of Use." This patent, which was developed by APR Applied Pharma Research s.a. (″APR″), a private, international corporation headquartered in Switzerland and focused on the development and commercialization of innovative healthcare products, is licensed exclusively to Tribute in Canada through a sub-license agreement with Depomed, Inc. (″Depomed″). Depomed has the exclusive North American rights to Cambia® licensed with APR. The issuance of the new patent will expand Tribute's intellectual property protection for Cambia®, currently indicated in Canada for the treatment of acute migraine in adults over 18 years of age.
"This important Canadian patent allowance extends our core intellectual property protection in a market that has been strategically significant to us since the initial launch of Cambia® in Canada in October 2012," stated Rob Harris, Tribute's President and Chief Executive Officer. "This new patent extends our intellectual property rights to June 6, 2026." IMS Health, an audited third party provider of sales data, reported an 89.2% increase in total prescriptions written for Cambia® during the three months ended September 30, 2015 compared to the three months ended September 30, 2014.
About Tribute
Tribute is a pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets. Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution), Uracyst® (sodium chondroitin sulfate solution 2%), Fiorinal®, Fiorinal® C, Visken®, Viskazide®, Collatamp® G, Durela®, Proferrin®, Iberogast®, MoviPrep®, Normacol®, Resultz®, Pegalax®, Balanse®, Balanse® Kids, Diaflor™, Mutaflor®, and Purfem® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to Fibricor® and its related authorized generic. In addition, it has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine, a product licensed from Faes Farma for the treatment of allergic rhinitis and chronic idiopathic urticaria (hives), in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. Bilastine is subject to receiving Canadian regulatory approval. Tribute also has the Canadian rights to ibSium®, which was approved in Canada in June 2015 and two additional pipeline products including Octasa® and BedBugz™, both of which are pending submission to Health Canada. Tribute's common shares are traded on the TSX Venture Exchange under the symbol "TRX" and on the OTCQX International under the symbol "TBUFF". For more detailed company information, including copies of this and other press releases, please visit www.tributepharma.com.